PMID- 36607862
OWN - NLM
STAT- MEDLINE
DCOM- 20230110
LR  - 20230127
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 102
IP  - 1
DP  - 2023 Jan 6
TI  - Change in left ventricular diastolic function after pioglitazone treatment in 
      patients with type 2 diabetes mellitus: A protocol for systematic review and 
      meta-analysis.
PG  - e32613
LID - 10.1097/MD.0000000000032613 [doi]
LID - e32613
AB  - BACKGROUND: Pioglitazone is currently used as an anti-diabetic agent and can 
      reduce cardiovascular events in in patients with type 2 diabetes mellitus (T2DM). 
      Left ventricular diastolic dysfunction has been recognized as an early 
      manifestation of myocardial dysfunction in T2DM patients. This systematic review 
      and meta-analysis aimed to investigate changes in the left ventricular diastolic 
      function after the treatment of pioglitazone. METHODS: A systematic literature 
      search of PubMed, Embase, and the Cochrane Library until May 2021 with keywords 
      pioglitazone and left ventricular diastolic function was performed in accordance 
      with the meta-analysis of observational studies in epidemiology guidelines and 
      preferred reporting items for systematic reviews and meta-analyses statement. 
      Three reviewers independently selected the studies and extracted data. Quality 
      assessment of the included studies was undergone. A fixed effects model was used 
      to calculate overall effect sizes. Subgroup analyses were subsequently performed. 
      A fixed effects model was used to calculate the overall effect size. Subgroup 
      analyses were then performed. RESULTS: Seven studies with 233 patients were 
      investigated. We found pioglitazone significantly improved hemoglobin A1c (%) in 
      patients with T2DM and left ventricular diastolic function had an improvement 
      tendency (weighted mean difference [WMD], 0.03; 95% confidence interval [CI], 
      0.01-0.05, P < .01) despite moderate heterogeneity (I2 = 66%). Subsequent 
      subgroup analysis indicated that left ventricular diastolic function were 
      significantly improved (WMD, 0.20; 95% CI, 0.12-0.29, P < .001) in T2DM patients 
      whose average age < 55 after receiving pioglitazone treatment. However, in T2DM 
      patients with mean age >/= 55 years, there was no significant improvement of left 
      ventricular diastolic function (WMD, 0.02; 95% CI, 0-0.04, P = .04). CONCLUSION: 
      Pioglitazone treatment significantly improved left ventricular diastolic function 
      in type 2 diabetic patients with a mean age of < 55 years, but did not improve 
      left ventricular diastolic function in patients with a mean age of >/= 55 years.
CI  - Copyright (c) 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Song, Han
AU  - Song H
AD  - Department of Cardiovascular Surgery, Qilu Hospital of Shandong University, 
      Jinan, Shandong, China.
FAU - Li, Yunye
AU  - Li Y
AD  - Department of Pharmacy, Qingdao Jiaozhou Central Hospital, Qingdao, Shandong, 
      China.
FAU - Yu, Ruiming
AU  - Yu R
AD  - Department of Cardiovascular Surgery, Qilu Hospital of Shandong University, 
      Jinan, Shandong, China.
FAU - Meng, Xiangbin
AU  - Meng X
AD  - Department of Cardiovascular Surgery, Qilu Hospital of Shandong University, 
      Jinan, Shandong, China.
FAU - Bi, Yanwen
AU  - Bi Y
AUID- ORCID: 0000-0003-1683-9727
AD  - Department of Cardiovascular Surgery, Qilu Hospital of Shandong University, 
      Jinan, Shandong, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - X4OV71U42S (Pioglitazone)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Humans
MH  - Middle Aged
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Pioglitazone/therapeutic use
MH  - Systematic Reviews as Topic
MH  - Meta-Analysis as Topic
MH  - Hypoglycemic Agents/therapeutic use
MH  - Ventricular Function, Left
PMC - PMC9829294
COIS- The authors have no funding and conflicts of interest to disclose.
EDAT- 2023/01/07 06:00
MHDA- 2023/01/11 06:00
PMCR- 2023/01/06
CRDT- 2023/01/06 13:33
PHST- 2023/01/06 13:33 [entrez]
PHST- 2023/01/07 06:00 [pubmed]
PHST- 2023/01/11 06:00 [medline]
PHST- 2023/01/06 00:00 [pmc-release]
AID - 00005792-202301060-00017 [pii]
AID - 10.1097/MD.0000000000032613 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2023 Jan 6;102(1):e32613. doi: 10.1097/MD.0000000000032613.